Tackling AMR in Europe's healthcare facilities

Ana Paula Coutinho Rehse
Technical Officer Infection Prevention and Control
WHO Regional Office for Europe
Global AMR Action Plan - Strategic Objectives


1. Improve awareness and understanding
2. Strengthen knowledge and evidence base
3. Reduce incidence of infection
4. Optimize use of antimicrobial medicines
5. Develop economic case for sustainable investment
Global activities

- World Antibiotic Awareness Week
- Global AMR Surveillance System (GLASS)
- Global Antibiotic Research & Development Partnership (GARDP)
- Core components of Infection Prevention and Control Programmes
- Global Priority Pathogens List of Antibiotic-Resistant Bacteria
- Updated Essential Medicines List update
Regional activities

- World Antibiotic Awareness Week
- European Antibiotic Awareness Week
- Central Asian and Eastern European Surveillance of Antimicrobial Resistance network (CAESAR)
- Antimicrobial Medicines Consumption network (AMC)
- Infection Prevention and Control core components
- Antimicrobial stewardship courses
- Tailoring AMR Programmes (TAP)
Surveillance of antimicrobial use and resistance

Antimicrobial Medicines Consumption network (AMC)

Central Asian and Eastern European Surveillance of Antimicrobial Resistance network (CAESAR)
<table>
<thead>
<tr>
<th>Specimen</th>
<th>Laboratory case definition</th>
<th>Surveillance type and sampling setting</th>
<th>Priority pathogens for surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>Isolation of pathogen from blooda</td>
<td>Selected sites or national coverage Continuous Patients in hospital and in the community</td>
<td>E. coli K. pneumoniae A. baumannii S. aureus S. pneumoniae Salmonella spp.</td>
</tr>
<tr>
<td>Urine</td>
<td>Significant growth in urine specimenb</td>
<td>Selected sites or national coverage Continuous Patients in hospital and in the community</td>
<td>E. coli K. pneumoniae</td>
</tr>
<tr>
<td>Faeces</td>
<td>Isolation of Salmonella spp. or Shigella spp. from stools</td>
<td>Selected sites or national coverage Continuous Patients in hospital and in the community</td>
<td>Salmonella spp. Shigella spp.</td>
</tr>
<tr>
<td>Urethral and cervical swabs</td>
<td>Isolation of N. gonorrhoeae</td>
<td>Selected sites or national coverage Continuous Patients in hospital and in the community</td>
<td>N. gonorrhoeae</td>
</tr>
</tbody>
</table>

CAESAR

GLASS
Antimicrobial stewardship

- Online course: “Antimicrobial Stewardship: A competency-based approach” (https://www.openwho.org/)
- Stewardship courses
- Pilot projects
Core components of infection prevention and control programmes at the national and acute health care facility level

- Core Component 1: IPC Programme
- Core Component 2: IPC Guidelines
- Core Component 3: IPC Training/Education
- Core Component 4: HAI Surveillance
- Core Component 5: Multimodal Strategies
- Core Component 6: Monitoring, audit & feedback
- Core Component 7: Workload, staffing & bed occupancy
- Core Component 8: Built environment, materials & equipment for IPC
Tailoring AMR Programmes (TAP)

• Knowledge alone not enough to change behaviour
• Methods/tools to design targeted behaviour change campaigns
• Based on behavioural science & social marketing
• Pilot projects
  – Ongoing: Sweden, England, Hungary, Kazakhstan, the former Yugoslav Republic of Macedonia
• Guidance document
<table>
<thead>
<tr>
<th></th>
<th>Hospital level</th>
<th>National level</th>
<th>Regional Level</th>
<th>Global Level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surveillance</strong></td>
<td>Adapt and adopt</td>
<td>Guidance</td>
<td>Guidance</td>
<td>Guidance</td>
</tr>
<tr>
<td></td>
<td>Data collection</td>
<td>National trends</td>
<td>Regional trends</td>
<td>Global trends</td>
</tr>
<tr>
<td></td>
<td>Data analysis</td>
<td>Feedback</td>
<td>Ref Laboratory</td>
<td>Ref Laboratory</td>
</tr>
<tr>
<td></td>
<td>Feedback</td>
<td>Nat Laboratory</td>
<td>Regional trends</td>
<td>Global trends</td>
</tr>
<tr>
<td></td>
<td>Local lab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antimicrobial Stewardship</strong></td>
<td>Adapt and adopt</td>
<td>National guidelines</td>
<td>Regional guidelines</td>
<td>Priority Pathogens</td>
</tr>
<tr>
<td></td>
<td>Monitoring and evaluation</td>
<td></td>
<td></td>
<td>List of Antibiotic-Resistant Bacteria</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Updated Essential Medicines List</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>List update</td>
</tr>
<tr>
<td><strong>Infection Prevention and</strong></td>
<td>Adapt and adopt</td>
<td>National guidelines</td>
<td>Implementatio n tools</td>
<td>Guidelines</td>
</tr>
<tr>
<td>Control</td>
<td>IPC core components</td>
<td></td>
<td></td>
<td>development</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Acknowledgments

• **Communications**
  – Cristiana Salvi

• **AMR Coordination**
  – Danilo Lo Fo Wong
  – Saskia Nahrgang
  – Marcello Gelormini
  – Ketevan Kandelaki
  – Karin Waefler

• **Health Technologies & Pharmaceuticals**
  – Garner Sarah
  – Kotoji Iwamoto

• **Infection Prevention and Control**
  – Ana Paula Coutinho Rehse

• **Food Safety and Zoonotic diseases**
  – Dina Pfeifer
  – Peter Sousa Hoejskov

• **High Threat Pathogens**
  – Joanna Zwetyenga

• **Vaccine Preventable Diseases & Immunization**
  – Siff Malue Nielsen
  – Katrine Habersaat
Thank you for your attention